CMS Open Payments · Program Year 2024
Evolution Surgical, Inc
Evolution Surgical, Inc reported $74,759.90 across General Payments, Research, and Ownership to 667 physicians and teaching hospitals across 667 transactions.
- $74.8K Below-median payer
- All-tracks total
- 667 Above-median volume
- Transactions
- 667 Above-median reach
- Recipients
- +$625.53
- General Payments vs PY2023
Evolution Surgical, Inc reported $74,759.90 across all CMS Open Payments tracks (General + Research + Ownership) to 667 physicians and teaching hospitals in Program Year 2024 - ranking #1256 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $74,759.90, averaging $112.08 per recipient.
How Evolution Surgical, Inc's $74.8K all-tracks total breaks down
Evolution Surgical, Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
20/100
Total payments
F
11/100
Transaction volume
F
15/100
Physician reach
F
15/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer evolution-surgical-inc Evolution Surgical, Inc
$74.8K · #1256/1,925 · 0.0% industry · PY2024
- TOT $74.8K
- RANK #1256
- SHARE 0.0%
- TXN 667
- RCP 667
- CAT 3
- GEN $74.8K
- ΔGEN +$625.53
- TOP1 14.7%
- PY 2024
Volume peers
Nearest volume peer: Aspira Women's Health Inc ($74.7K)
Evolution Surgical, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Evolution Surgical, Inc's CMS-reported General Payments increased by $625.53 (+0.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: EVOLUTION SURGICAL, INCPY2023: EVOLUTION SURGICAL, INCPY2024: Evolution Surgical, Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $74,134.37
- PY2024
- $74,759.90
What the Data Shows for Evolution Surgical, Inc
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Evolution Surgical, Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 3-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Travel and Lodging" at $37.4K, accounting for 50.0% of this company's General Payments and 103 transactions.
General Payment Breakdown by Type
Evolution Surgical, Inc made 3 types of general payments. "Travel and Lodging" is the largest category at $37.4K, 50.0% of General Payments.
How Evolution Surgical, Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $37.4K | 103 | 50.0% |
| Food and Beverage | $26.4K | 561 | 35.3% |
| Charitable Contribution | $11.0K | 3 | 14.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $21,296.14 (28.5%) of $74,759.90 in this company's General Payments records across 349 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Evolution Surgical, Inc
The five named recipients with the highest reported General Payments from this company
- 1
Langley Porter Psychiatric Hospital
$11,000.00 across 3 reported transactions
- 2
Paul Kim
$3,419.75 across 13 reported transactions
- 3
Parneet Kaur
$2,791.52 across 7 reported transactions
- 4
Semon Bader
$2,610.02 across 12 reported transactions
- 5
Daniel Thuillier
$1,474.85 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Evolution Surgical, Inc's spend rank (#1256 of 1,925, bottom 35% by spend) and concentration rank (#1,437 of 1,838, bottom 22% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Eli Lilly Export S.A. Puerto Rico Branch : $47.2K total payments, HHI 334
- Profound Medical Corp. : $125.2K total payments, HHI 329
- Argenx US, Inc. : $3.5M total payments, HHI 327
- DC Dental, LLC : $12.9K total payments, HHI 327
- Intra-Sana Laboratories : $291.3K total payments, HHI 327
- KLS-Martin L.P. : $5.3M total payments, HHI 326
- Evolution Surgical, Inc (this company) : $74.8K total payments, HHI 324
- Sanofi Pasteur Inc. : $1.9M total payments, HHI 323
- SomnoMed Inc. : $20.8K total payments, HHI 323
- Tolmar, Inc. : $420.1K total payments, HHI 322
- Ancora Heart, Inc. : $136.9K total payments, HHI 320
- Ucb SA : $1.1M total payments, HHI 317
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Evolution Surgical, Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Evolution Surgical, Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Evolution Surgical, Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Ascend Therapeutics US, LLC
Lightbody Medical Technologies Inc
Pinnacle Biologics, Inc
Medexus Pharma, Inc.
Clariance SAS
Put this to use
Evolution Surgical, Inc ranks #1256 of 1,925 by all-tracks total payments, led by "Travel and Lodging".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Travel and Lodging" spend across every manufacturer, not just Evolution Surgical, Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.